Latest news for  (OTC:AHLAS) Stock

TD Cowen analyst Matthew Ramsay maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Hold and raises the price target from $90 to $110.

News

Price Target

Analyst Ratings

SWKS

TD Cowen Maintains Hold on Skyworks Solutions, Raises Price Target to $110

Barclays analyst Julian Mitchell maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and lowers the price target from $384 to $368.

HUBB

Barclays Maintains Equal-Weight on Hubbell, Lowers Price Target to $368

Federal Reserve

Fed's Powell Says Economy Not Extremely Bad, Just Pockets of Weakness; No Decision Made About Future Meetings

Barclays analyst Raimo Lenschow maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Equal-Weight and lowers the price target from $15 to $14.

FRSH

Barclays Maintains Equal-Weight on Freshworks, Lowers Price Target to $14

TD Cowen analyst Dan Brennan maintains GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) with a Buy and raises the price target from $46 to $50.

TD Cowen Maintains Buy on GeneDx Hldgs, Raises Price Target to $50

Goldman Sachs analyst Michael Ng reiterated a Neutral rating on Sofi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings">price target of $7.50</a>.
Ng noted Sofi Technologies upgraded its full-year <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40032979/sofi-technologies-reports-net-revenue-of-599-million-and-net-income-of-17-million-for-q2-2024-mark" rel="noreferrer noopener">net income outlook</a> to $175 million—$185 million (versus $165 million—$175 million prior).
The analyst writes that adjusted EBITDA margins should continue to ramp throughout the year to 25% for the full year 2024 as the company optimizes its capital structure towards using lower-cost deposits as a funding source and improves unit economics on Credit Card and Investment products within the Financial Services segment.
Ng flagged that Financial Services growth was primarily due to improved monetization driven by higher deposits and spending levels within SoFi Money, more significant AUM within SoFi Invest, and an increase in Credit Card spending.
Sofi Technologies&#8217; deposits totaled $23.0 billion at quarter-end (versus $21.6 billion at fiscal 2024 first-quarter). Ng noted continued growth in deposits to reduce reliance on warehouse funding.
In the second quarter, lending revenue of $339 million beat Goldman Sachs&#8217; estimate and consensus of $284 million and $300 million, driven by a ~$1 billion beat in personal loan originations ($4.2 billion versus Goldman Sachs&#8217; estimate and consensus of $3.2 billion).
According to Sofi Technologies, it was able to drive origination growth while maintaining stringent underwriting standards.
In addition, the company&#8217;s second-quarter 90-day personal loan delinquency rate decreased to 64 bps (versus 72 bps in the first quarter).
Loan performance will remain in focus given that Sofi Technologies&#8217; personal loan annualized net charge-off rate of 3.84% (up versus 3.45% in the first quarter) was flattered by a $69 million delinquent loan asset sale in the quarter (~5.4% adjusted for this), the analyst said.
He said that personal loan origination volumes of $4.2 billion were well above Goldman Sachs and Visible Alpha&#8217;s consensus of $3.2 billion despite increasing concerns about consumer health. However, Sofi Technologies&#8217; customer base skews prime.
Separately, Sofi Technologies lowered its outlook for Tech Platform segment growth for 2024 to mid-to-high teens percentage (versus 20% yoy growth prior) as large deals take longer to ramp than expected, particularly in Latin America.
That said, other elements of Sofi Technologies&#8217; outlook were encouraging, including a raised outlook for Financial Services segment growth and deposits growth and Sofi Technologies&#8217; third consecutive quarter of positive GAAP net income.
Ng increased his fiscal 2024, 2025, and 2026 revenue estimates by 5% on average to reflect Sofi Technologies&#8217; latest outlook for personal lending &amp; financial services.
Ng projected fiscal 2024 revenue and EPS of $2.52 billion (prior $2.50 billion) and $0.11 (prior $0.08). The analyst expects fiscal 2025 revenue and EPS of $3.02 billion (prior $2.87 billion) and $0.25 (prior $0.12). He estimates fiscal 2026 revenue and EPS of $3.81 billion (prior $3.49 billion) and $0.56 (prior $0.35).
Price Action: SOFI shares are trading higher by 4.04% to $7.725 at last check Wednesday. 
Photo via Shutterstock

Analyst Color

Fintech news covering the emerging Financial Technology services sector

Fintech

Reiteration

Movers

Tech

Trading Ideas

SOFI

Sofi Tech's Lending And Financial Services Momentum Well Above Estimates: Goldman Sachs Raises Forecast

Barclays analyst David Anderson maintains Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) with a Underweight and raises the price target from $21 to $24.

Barclays Maintains Underweight on Oceaneering International, Raises Price Target to $24

Fed's Powell Says Many Perceived Pieces of Wisdom Haven't Worked, Situation Has Been Unique; Can't Look to History as a Guide to Future

Barclays analyst David Anderson maintains Expro Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPRO#NYSE">XPRO</a>) with a Overweight and raises the price target from $27 to $28.

XPRO

Barclays Maintains Overweight on Expro Gr Hldgs, Raises Price Target to $28

TD Cowen analyst Gary Taylor maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Buy and raises the price target from $80 to $89.

TD Cowen Maintains Buy on Centene, Raises Price Target to $89

WIIM

GTES

Gates Industrial shares are trading higher following Q2 earnings.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 400 points on Wednesday.
The Dow traded up 1.07% to 41,177.51 while the NASDAQ rose 3.10% to 17,678.79. The S&amp;P 500 also rose, gaining, 2.08% to 5,549.42.
Leading and Lagging Sectors Information technology shares jumped by 4.3% on Wednesday.
In trading on Wednesday, health care shares rose by just 0.1%.
Top Headline Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected earnings and sales results for its fourth quarter on Tuesday.
Intelligent Cloud segment revenue was $28.5 billion, up 19% year-over-year, while Azure and other cloud services revenue posted year-over-year growth of 29% last quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares shot up 40% to $186.83 after the company reported better-than-expected Q3 GAAP EPS and sales.</li>
<li>Shares of Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) got a boost, surging 24% to $122.84&nbsp;after the company reported better-than-expected first-quarter financial results.</li>
<li>Fiverr International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) shares were also up, gaining 22% to $26.78 after the company reported better-than-expected second-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares dropped 61% to $1.31 after the company announced a&nbsp;$10 million&nbsp;registered direct offering of 5 million&nbsp;shares of common stock with unregistered warrants at a price of&nbsp;$2&nbsp;per unit.</li>
<li>Shares of FibroGen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) were down 45% to $0.5640. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.</li>
<li>PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) was down, falling 35% to $11.05. The company announced clinical data from the first dose cohort of PGN-EDO51.</li>
</ul>
Commodities In commodity news, oil traded up 4.3% to $77.96 while gold traded up 1% at $2,476.40.
Silver traded up 1.5% to $28.945 on Wednesday, while copper rose 2.8% to $4.1965.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.80%, Germany's DAX rose 0.53% and France's CAC 40 gained 0.76%. Spain's IBEX 35 Index fell 1.23%, while London's FTSE 100 rose 1.13%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.49%, Hong Kong's Hang Seng Index jumping 2.01% and S&amp;P BSE Sensex gaining 0.35%.
Economics
<ul>
<li>U.S. pending home sales rose by 4.8% from the prior month in June compared to a revised contraction of 1.9%.</li>
<li>U.S. crude oil inventories declined by 3.436 million barrels in the week ended July 26th, above market estimates of a 1.6 million barrel draw.</li>
<li>Private businesses in the U.S. added 122,000 workers to their payrolls in July, versus a revised 155,000 in June.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">&#8216;</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

Markets

FGEN

FVRR

IMNN

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

Fed's Powell Says Well Positioned to Respond to Any Economic Weakness, Though Not Currently Observed; Plenty of Room to Act if Weakness Arises; Wage Gains Remain High; Data Indicates Labor Market Normalizing; Job Vacancies Still High by Historical Standards

During the last three months, 4 analysts shared their evaluations of First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $55.5, along with a high estimate of $60.00 and a low estimate of $50.00. This upward trend is apparent, with the current average reflecting a 5.21% increase from the previous average price target of $52.75.
<img src="https://www.benzinga.com/files/images/story/2024/1722452512_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of First Industrial Realty by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Industrial Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Industrial Realty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for First Industrial Realty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of First Industrial Realty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Industrial Realty analyst ratings.</a>
<h2>Get to Know First Industrial Realty Better</h2>
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. First Industrial's real estate portfolio is comprised of light industrial properties, which are split between industrial and office space, and bulk warehouse properties generally located in business parks near transportation hubs. While light industrial buildings represent a share of First Industrial's holdings, bulk warehouses make up the majority of its portfolio's square footage. The company derives the vast majority of its revenue from rental income tied to medium-term leases. First Industrial's customers include manufacturing, retail, wholesale trade, distribution, and professional services companies.
<h3>Financial Milestones: First Industrial Realty's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: First Industrial Realty's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 31.24%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): First Industrial Realty's ROE stands out, surpassing industry averages. With an impressive ROE of 1.97%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): First Industrial Realty's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.99% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: First Industrial Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down First Industrial Realty: 4 Analysts Share Their Views

Barclays analyst Pablo Monsivais maintains Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) with a Overweight and lowers the price target from $40 to $38.

VTMX

Barclays Maintains Overweight on Corporacion Inmobiliaria, Lowers Price Target to $38

Analysts' ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $37.17, a high estimate of $53.00, and a low estimate of $26.00. Experiencing a 16.47% decline, the current average is now lower than the previous average price target of $44.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722452497_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>Financial Insights: AtriCure</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 16.43%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AtriCure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.2%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

Navigating 6 Analyst Ratings For AtriCure

Maker's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>) price has increased 3.47% over the past 24 hours to $2,874.89. Over the past week, MKR has experienced an uptick of over 7.0%, moving from $2,664.68 to its current price. As it stands right now, the coin's all-time high is $6,292.31. 
The chart below compares the price movement and volatility for Maker over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1722452475_0.png" alt="price_chart" />
The trading volume for the coin has decreased 18.0% over the past week, while the overall circulating supply of the coin has decreased 0.28% to over 930 thousand. This puts its current circulating supply at an estimated 92.51% of its max supply, which is 1.01 million. The current market cap ranking for MKR is #36 at $2.67 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1722452475_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MKR

Cryptocurrency Maker Up More Than 3% In 24 hours

Fed's Powell Says We Examine Private Demand Carefully; Balancing Risks of Acting Too Soon or Too Late; Facing a Very Difficult Judgment Call on Rates; All 19 Participants Supported Today's Decision; Real Discussion Held on Case for Reducing Rates at This Meeting; Strong Majority Supported Keeping Rates Unchanged at This Meeting; Policy Lags Starting to Show in Economy Over Last 6 Months; Feels Positive About Current Position

Across the recent three months, 5 analysts have shared their insights on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.2, a high estimate of $40.00, and a low estimate of $27.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.7%. 
<img src="https://www.benzinga.com/files/images/story/2024/1722452475_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Sean McCutcheon</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$40.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Xencor compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Xencor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xencor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xencor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Xencor</h2>
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
<h3>Xencor: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Xencor faced challenges, resulting in a decline of approximately -32.47% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Xencor's net margin excels beyond industry benchmarks, reaching -531.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Xencor's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.62%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.15, Xencor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XNCR

Decoding 5 Analyst Evaluations For Xencor

Regulators in Oregon have granted the first-ever state license for the production of psilocybin edibles, marking a significant milestone in the nation&#8217;s burgeoning <a href="https://www.benzinga.com/markets/psychedelics">psychedelic industry</a>. As <a href="https://www.marijuanamoment.net/oregon-regulators-grant-first-license-to-psilocybin-edibles-manufacturer-company-announces/">reported</a> by Marijuana Moment, Spiritus Oregon, a Southeast Portland company, announced last week that it received the inaugural Psilocybin Edibles license, positioning it as the first legal manufacturer of psilocybin-infused edibles.
<h3 class="wp-block-heading">Legal Snd Industry Scenery In Oregon</h3>
With the <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">decriminalization of drug possession</a> in 2020, Oregon also moved forward with the first state-licensed psilocybin-assisted therapy system. Since then, the Oregon Health Authority (OHA) had issued the <a href="https://www.benzinga.com/markets/cannabis/23/03/31532765/legal-psychedelics-in-us-oregon-approves-growers-license-colorado-advances-advisory-council">first manufacturer license</a> to Satori Farms PDX LLC, a woman-owned business, in March 2023. Various licenses were later distributed, including the state&#8217;s <a href="https://www.benzinga.com/markets/cannabis/22/10/29189664/oregons-psilocybin-services-act-begins-granting-licenses-for-training-therapy-providers">first psilocybin facilitator</a>, <a href="https://www.benzinga.com/markets/cannabis/24/05/38732317/pot-company-gets-license-to-open-psilocybin-service-center-the-sacred-mushroom-in-oregon">service center</a> and lab testing licenses. Earlier this year, Gov. Tina Kotek signed a bill <a href="https://www.benzinga.com/markets/cannabis/24/04/38113294/psychedelics-reform-update-missouris-10m-budget-maines-marylands-study-groups-oregons-re-crim-an">recriminalizing drug possession</a>, adding another layer of complexity to the state&#8217;s evolving drug policy landscape.
<h3 class="wp-block-heading">Spiritus Oregon Leads The Way</h3>
Spiritus Oregon, known for its Horizon Edibles brand, will soon offer products like &#8220;dark chocolates precisely dosed with dried, homogenized mushrooms,&#8221; which blend chocolate-forward flavors with nutty and earthy notes from the mushrooms. &#8220;Our products, like our mushroom chocolates, are meant to be eaten,&#8221; said Michael Briggs, president of Horizon Edibles. &#8220;We wanted them to be as safe or safer than consuming a dried mushroom. Customers expect products to be as safe as anything they would buy in a grocery store and we're here to provide that.&#8221;
<h3 class="wp-block-heading">Precision Dosing And Safety Standards</h3>
Spiritus Oregon not only produces its own line of psilocybin edibles but also offers white-label products. According to its website, the company operates a commercial kitchen under the Horizon Edibles brand. The company prides itself on dosing precision, claiming standards that allow only a 0.5-milligram deviation on larger doses (20 mg to 50 mg of psilocybin) and a 0.2 mg deviation on microdoses (2 mg to 5 mg). This is in stark contrast to Oregon&#8217;s allowance of a 20% deviation, which Horizon argues could lead to a &#8220;wildly different experience&#8221; for consumers.
&#8220;People should trust that they'll have a consistent experience—something that lines up with their expectations. These treatments can be expensive and we want to ensure customers are getting exactly what they're paying for,&#8221; said Briggs. &#8220;A major problem with psilocybin treatment can be how variable it is. We have solved that problem.&#8221;
<h3 class="wp-block-heading">Health Benefits</h3>
Horizon Edibles also highlights the health benefits of their manufacturing process, which removes the chitin &#8211; the fibrous component of mushrooms that can cause gastrointestinal distress. &#8220;Mushrooms with psychoactive properties are often hard on the stomach, with a fiber made of chitin, the same material that makes up crab shells,&#8221; the company noted. &#8220;Horizon Edibles' process extracts actives (psychoactives) of all types and fully removes the chitin, resulting in easier digestion.&#8221;
<h3 class="wp-block-heading">Legal And Industry Challenges</h3>
Despite these advances, Oregon&#8217;s legal psilocybin industry faces challenges. A newly filed federal lawsuit against Oregon officials claims the state&#8217;s psilocybin law discriminates against disabled people who cannot travel to designated service centers, thereby denying them potential health benefits. The lawsuit, filed in U.S. District Court in Oregon, argues that state law restricts psilocybin services to licensed centers, preventing many disabled and terminally ill individuals from accessing treatment.
<h3 class="wp-block-heading">The Road Ahead </h3>
Recent reports suggest that Oregon&#8217;s legal psilocybin sector is struggling to attract paying clients, despite initial enthusiasm. Psilocybin service providers and entrepreneurs gathered at a recent conference in Portland to reflect on a year of transformative experiences for clients but also faced numerous challenges, including regulatory hurdles and inconsistent demand.
Cover image made with AI

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

News

Latest news for (OTC:AHLAS) Stock